REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Clinical trials for REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE trials appear
Sign up with your email to follow new studies for REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail offers hope for kids with relapsed leukemia
Disease control OngoingThis study tests two drugs, selinexor and venetoclax, given together with standard chemotherapy for children and young adults whose acute myeloid leukemia (AML) has returned or not responded to treatment. The main goal is to find the safest dose and see how well the combination w…
Matched conditions: REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Promising new combo targets Hard-to-Treat infant leukemia
Disease control OngoingThis study tests a new oral drug (revumenib) combined with standard chemotherapy for infants and young children with a specific type of leukemia (KMT2A-rearranged) that has returned or not responded to treatment. The goal is to see if the combination is safe and works better than…
Matched conditions: REFRACTORY ACUTE LEUKEMIA OF AMBIGUOUS LINEAGE
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC